variable. It is only through more logical and thoughtful considerations that better treatment decisions will be made and patient outcomes enhanced. Future research in this area need to move towards evaluating therapeutic approaches based on 'significance of PDA shunting' rather than its mere presence.
which suggests that a 'less aggressive' approach to the management of the patent ductus arteriosus (PDA) may be acceptable. Their approach is based on a strategy of modest fluid restriction and relatively more rigorous clinical and echocardiography criteria for diagnosing significant PDA, which were then selected for treatment with indomethacin and surgical ligation. The authors report a reduction in indomethacin use, older age at indomethacin commencement and surgical ligation, but rates of surgical ligation remained unchanged. They conclude that despite this conservative approach to management of the ductus arteriosus, individual neonatal outcomes were not adversely affected, but an increase was seen in the combined outcome of mortality after 7 days and chronic lung disease.
We compliment the authors for sharing their experience of rationalizing PDA treatment and hence providing further evidence that not all patients with a PDA require early ductal closure. It is our opinion that the impact of PDA on patient outcomes is more likely to be a function of magnitude of shunt, rather than its mere presence. In this letter, we will like to highlight certain methodological and interpretative concerns regarding the data in this report. First, number of infants in era 2 is almost half of era 1, making comparison challenging. It can be argued that the study had insufficient power to reach statistical significance for various clinically relevant outcomes. For instance, the rates of pulmonary hemorrhage more than doubled, spontaneous perforation halved but mortality rose by 62% in era 2, none of which reached statistical significance. A carefully matched case-control study could have yielded a more appropriate comparison. Second, in more than 90% of infants, the diagnosis of PDA was confirmed using echocardiography but authors failed to provide any data to demonstrate that characteristics of the ductus arteriosus, particularly those related to the magnitude of the shunt, were comparable between epochs. The high baseline rate of indomethacin use during era 1 (79% of all very low birth-weight infants) is suggestive that some patients with small restrictive ducts or with low-volume shunts may have been treated. This is further supported by their finding of similar rates of PDA ligation in both eras. It could be argued that a more refined approach to treatment, based on enhanced definition of the hemodynamic impact of the shunt using clinical and echocardiography criteria, may have resulted in a better balance between avoidance of unnecessary treatment when the ductus is patent but the shunt volume is low and the approach to minimize morbidities associated with prolong exposure to highmagnitude ductal shunt. Third, the authors report a lack of change in grade III/IV intraventricular hemorrhage between epochs. This is not surprising, as the age at initiation of indomethacin in both eras was beyond the point at which intervention could have had an impact. We hypothesize that the reduction in intraventricular hemorrhage seen in trials of prophylactic indomethacin, early intervention trials and epoch-based reports of early targeted intervention relates to timely optimization of systemic hemodynamics. [2] [3] [4] Prospective observational physiologyical studies of the transitional circulation demonstrate low systemic blood flow in the first few hours of life leading to relative cerebral hypo-perfusion.
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As pulmonary vascular resistance falls, with consequential increased transductal resistance, the magnitude of the ductal shut increases leading to higher left heart preload and relatively acute rise in preductal cardiac output. This may create the potential of a cerebral hypo-hyperperfusion state which, depending on the patient's cerebral auto regulatory capacity, may contribute, at least in part, to the nature and extent of intraventricular hemorrhage. Finally, one of the rationales mentioned by authors for adopting the more tolerant approach was the associated risks of treatment.
Considering the significant reduction in use of indomethacin (79% vs 26%), one would have expected a reduction in treatmentassociated morbidities, but data is not provided to support this counter argument to use of indomethacin. Despite the abovementioned methodological and interpretative limitations of this study, there remains an important non-reassuring association of increase in the composite outcome of chronic lung disease or mortality after day 7, which may support the notion that there are 'some patients' who may benefit from early ductal closure. The recommendation of modest fluid restriction as an alternative to ductal closure is premature and somewhat concerning. Biologically, such an approach may reduce pulmonary overcirculation but at the expense of compromising end-organ blood flow in patients already suffering from the 'ductal steal'. The recent article by Buyst et al. 6 emphasizes this point, where fluid restriction as a exclusive treatment strategy led to compromised systemic blood flow without any demonstrable beneficial effect on pulmonary hemodynamics or lung compliance.
We would like to caution neonatologists regarding the interpretation of studies, which appear to argue against treatment of 'all' patients with a PDA. The sole argument presented by those opposed to therapeutic intervention is that randomized trials have not shown improvements in long-term outcomes and reports of short-term benefits are conflicting. This is not surprising as majority of published trials of therapeutic intervention have an inherent limitation of failing to standardize the definition of hemodynamic significance. Inclusion of patients where the ductus was patent but not hemodynamically significant, irrespective of transductal diameter, may minimize the likelihood of identifying any real beneficial impact on outcomes related to altered pulmonary or systemic perfusion.
The neonatology academic community has become engaged in a futile debate between 'treat all' vs 'treat none'. The physiology of the ductus arteriosus and determinants of transductal flow does not lend itself towards such a dichotomous situation. The contributions by Bose and Laughon, 7 Benitz, 8 which suggest a permissive approach to the ductus arteriosus, serve as an important lesson to neonatologists regarding alternative approaches to ductal care but must not be interpreted as avoidance of ductal closure 'at all costs'. As we re-learn how to utilize cardiovascular physiology and rationalize decision making, it is becoming clearer that there are 'some patients' who truly benefit from intervention and earlier treatment is likely to greater benefit, whereas other patients, who perhaps have received treatment in the past, do not require intervention. In our opinion, neonatologists need to evolve away from thinking of 'ductal patency and consider 'magnitude of transductal flow' as the more relevant physiological and clinical 
Reply to McNamara and Jain
Journal of Perinatology (2013) 33, 249; doi:10.1038/jp.2012.106
We thank Drs McNamara and Jain for their thoughtful letter and recognize their important contributions to our understanding of patent ductus arteriosus (PDA) physiology. 1 On the whole, my coauthors and I agree with their salient points: (1) deleterious effects of a PDA are likely related to the magnitude and duration of the left-to-right shunt, and these data are generally not documented in PDA publications (including ours, although we made some progress in this regard), (2) small restrictive PDAs likely have been overtreated in past years (and our study specifically avoided this pitfall), (3) standardizing the definition of hemodynamic significance is paramount to refining rational PDA therapy.
A few points of clarification are important in regard to their questions. First, we clearly specify in the Methods that our investigation was prospectively designed to be 18 months. This was done not for convenience, but because we wanted a sufficient number of VLBW infants with PDAs treated with the new permissive protocol, to compare with the 139 control PDA infants born in the previous 36 months, a time period when cardiorespiratory therapy was traditional and relatively uniform. We were appropriately cautious as we wanted to minimize potential deleterious events related to untreated PDAs, yet have enough patients to make meaningful comparisons between Era 1 and Era 2. This was uncharted waters and there was some reticence. We think we struck a reasonable balance and our investigation is the largest published study that carefully documents a wide variety of NICU outcomes related to permissive PDA therapy.
Second, the major finding of our study (a higher rate of the combined outcome of death or chronic lung disease in Era 2) is concerning, and clearly stated in both the Results and Discussion. We write that this is both biologically plausible and an urgent issue to clarify in a RCT. We concur that clinical and echocardiographic staging of the PDA would be a wise way to parcel the study infants, something that has not been done as yet. Our Era 2 experience does lend support to a permissive PDA arm in a RCT (see Figure 1) , ideally enhanced by the hemodynamic staging that Drs McNamara and Jain suggest. Of note, Sosenko et al. 2 have recently published a small RCT showing that delayed pharmacologic closure therapy until a 'hemodynamically significant' PDA was present did not improve or worsen NICU outcomes. Echocardiographic staging of the type Drs McNamara and Jain suggest was not documented.
Third, although fluid status may indeed affect end-organ perfusion, we doubt the statistically significant Era 2 decrease of 10 ml kg À 1 /day in total fluids on days 1-28 was clinically significant. Fourth, Drs McNamara and Jain will be interested to know that based upon our initial study (essentially a reasoned quality improvement project), we have extended the analysis of our permissive PDA therapy to three additional NICUs, which has increased our total number of PDA infants from 211 to 369. This larger experience will shed light on rational PDA therapy and has been submitted for publication.
